- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Ernexa Therapeutics Inc.: Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients | 1 | GlobeNewswire (USA) | ||
| 17.06. | Ernexa treibt Zelltherapie voran: Klinische Studie für dieses Jahr geplant | 3 | Investing.com Deutsch | ||
| 17.06. | Ernexa advances cell therapy toward clinical trial this year | 3 | Investing.com | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study | 731 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| 09.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer | 2 | GlobeNewswire (USA) | ||
| 27.05. | Ernexa Therapeutics treibt IND-Antrag für Zelltherapie-Kandidaten ERNA-101 für Q3 voran | 1 | Investing.com Deutsch | ||
| 27.05. | Ernexa Therapeutics advances ERNA-101 toward Q3 IND filing | 2 | Investing.com | ||
| 27.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development | 141 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| 20.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity | 1 | GlobeNewswire (USA) | ||
| 11.05. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 | 2 | GlobeNewswire (USA) | ||
| 06.05. | Ernexa-Aktie schießt nach Studienergebnissen zu Eierstockkrebs um 40 % in die Höhe | 10 | Investing.com Deutsch | ||
| 06.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | 314 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| 04.05. | Ernexa Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down | 2 | Seeking Alpha | ||
| 30.04. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split | 208 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| 31.03. | Ernexa plant klinische Studie für Zelltherapie ERNA-101 bei Eierstockkrebs | 1 | Investing.com Deutsch | ||
| 31.03. | Ernexa plans ovarian cancer trial for cell therapy ERNA-101 | 1 | Investing.com | ||
| 31.03. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 | 186 | GlobeNewswire (Europe) | Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,398 | +2,86 % | Clinuvel Pharmaceuticals Limited: CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study | EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its "totality of evidence" approachcentral photographic review and validated disease... ► Artikel lesen | |
| EDITAS MEDICINE | 3,000 | +5,63 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,914 | +0,44 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,800 | +0,72 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,094 | -3,87 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| CYTODYN | 0,190 | -17,39 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 7,395 | +0,75 % | Emergent BioSolutions Secures $52.7 Million U.S. Government Contract Modification For ACAM2000 | ||
| DENALI THERAPEUTICS | 22,560 | +0,18 % | Optionshandel bei Denali Therapeutics zieht stark an | ||
| CEL-SCI | 0,850 | 0,00 % | CEL SCI CORP - 8-K, Current Report | ||
| CYTOKINETICS | 75,84 | +1,69 % | UBS upgrades Cytokinetics stock rating on Myqorzo launch strength | ||
| COHERUS ONCOLOGY | 1,260 | +1,69 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,176 | -5,95 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| FAETH THERAPEUTICS | 23,095 | -7,62 % | Baird initiates Faeth Therapeutics stock with outperform rating | ||
| FATE THERAPEUTICS | 2,650 | +11,53 % | Globaler Biotech-Wettlauf und die Zukunft der Plattformstrategie - Warum Mesoblast auf den Pfaden von großen Konzernen wie Merck KGaA wandert | ||
| CYBIN | 5,600 | -2,27 % | Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results | - Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1- 2,3, EMBRACE, for... ► Artikel lesen |
Das Unternehmen ERNEXA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,45 % bei einem Aktienkurs von 6,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.